AD 223
Alternative Names: AD-223Latest Information Update: 16 Feb 2024
At a glance
- Originator Addpharma
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential hypertension
Most Recent Events
- 31 Jan 2024 Phase-III clinical trials in Essential hypertension (Combination therapy) in South Korea (PO) (NCT06052748)
- 25 Sep 2023 Addpharma plans a phase III trial for Hypertension (Combination therapy) in South Korea (PO) (NCT06052748)
- 25 Sep 2023 Clinical trials in Essential hypertension in South Korea (PO) before September 2023 (NCT06052748)